146 related articles for article (PubMed ID: 34921125)
1. Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Huang L; Tian M; Liu Z; Liu C; Fu R
J Investig Med; 2022 Apr; 70(4):953-962. PubMed ID: 34921125
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
3. Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.
Punzo F; Tortora C; Argenziano M; Casale M; Perrotta S; Rossi F
PLoS One; 2018; 13(12):e0208102. PubMed ID: 30507954
[TBL] [Abstract][Full Text] [Related]
4. Effects of Iron Chelation in Osteosarcoma.
Argenziano M; Di Paola A; Tortora C; Di Pinto D; Pota E; Di Martino M; Perrotta S; Rossi F; Punzo F
Curr Cancer Drug Targets; 2021; 21(5):443-455. PubMed ID: 33380300
[TBL] [Abstract][Full Text] [Related]
5. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
6. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
7. Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia.
Zhang R; Han B
J Clin Pharm Ther; 2022 Oct; 47(10):1619-1626. PubMed ID: 35748618
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X
Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
10. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Musto P; Maurillo L; Simeon V; Poloni A; Finelli C; Balleari E; Ricco A; Rivellini F; Cortelezzi A; Tarantini G; Villani O; Mansueto G; Milella MR; Scapicchio D; Marziano G; Breccia M; Niscola P; Sanna A; Clissa C; Voso MT; Fenu S; Venditti A; Santini V; Angelucci E; Levis A
Br J Haematol; 2017 Jun; 177(5):741-750. PubMed ID: 28419408
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
Comont T; Meunier M; Cherait A; Santana C; Cluzeau T; Slama B; Laribi K; Giraud JT; Dimicoli S; Berceanu A; Le Clech L; Cony-Makhoul P; Gruson B; Torregrosa J; Sanhes L; Jachiet V; Azerad MA; Al Jijakli A; Gyan E; Gaudin C; Broner J; Guerveno C; Guillaume T; Ades PL; Beyne-Rauzy O; Fenaux P;
Br J Haematol; 2021 Jul; 194(2):336-343. PubMed ID: 34151423
[TBL] [Abstract][Full Text] [Related]
12. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
Cheng WY; Said Q; Hao Y; Xiao Y; Vekeman F; Bobbili P; Duh MS; Nandal S; Blinder M
Curr Med Res Opin; 2018 Nov; 34(11):1959-1966. PubMed ID: 29701080
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.
Vlachodimitropoulou E; Chen YL; Garbowski M; Koonyosying P; Psaila B; Sola-Visner M; Cooper N; Hider R; Porter J
Blood; 2017 Oct; 130(17):1923-1933. PubMed ID: 28864815
[TBL] [Abstract][Full Text] [Related]
15. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
[TBL] [Abstract][Full Text] [Related]
16. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
Calabrese C; Panuzzo C; Stanga S; Andreani G; Ravera S; Maglione A; Pironi L; Petiti J; Shahzad Ali MS; Scaravaglio P; Napoli F; Fava C; De Gobbi M; Frassoni F; Saglio G; Bracco E; Pergolizzi B; Cilloni D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081324
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
19. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Shammo JM; Komrokji RS
Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
